nach oben

Psychiatric Quarterly

Erschienen in:

03.08.2021 | Original Paper

Global Scientific Outputs of Schizophrenia Publications From 1975 to 2020: a Bibliometric Analysis

verfasst von: Seda Kiraz, Emre Demir

Erschienen in: Psychiatric Quarterly | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Schizophrenia is a choronic, complex and powerfully inherited mental illness that seriously affects quality of life. The illness is one of the most researched psychiatric disorders from past to present. This study aims to provide a holistic summary of the global scientific outputs through bibliometric analyses and reveal the trend topics. The articles published between the years 1975 and 2020 were downloaded from the Web of Science (WoS) database and analyzed using bibliometric methods. The literature review was conducted using the keyword ‘‘schizophren*’’ in the ‘‘Research Area’’ category. The relation between the number of publications of the countries and the Gross Domestic Products and Human Development Index values were analyzed using Spearman’s correlation coefficient. The number of articles between the years 2021 and 2032 was estimated through linear regression analysis.There were 103,992 publications, 51,117 of which were articles. The number of studies has increased in direct proportion to the development level of the countries. Schizophrenia Research was the most active journal. The most used research topics are cognition, negative symptoms, bipolar disorder, antipsychotics, depression, clozapine, quality of life. Trend keywords used in recent years are ‘inflammation’, ‘biomarker’, ‘oxidative stress’, ‘Brain Derived Neurotrophic Factor (BDNF)’, ‘social cognition’, ‘metacognition’, ‘motivation’, ‘social functioning’, ‘functioning’, ‘mental health’, ‘metabolic syndrome’, ‘functional connectivity’, ‘adherence’ and ‘recovery’ indicated new research frontiers in this field. Although schizophrenia has not been fully elucidated, studies are growing like an avalanche. Our study includes the most up-to-date and most comprehensive data ever made in this field.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC; 2020.

Maroney M. An update on current treatment strategies and emerging agents for the management of schizophrenia. Am J Manag Care. 2020;26(3 Suppl):55–61. https://doi.org/10.37765/ajmc.2020.43012.CrossRef

McCutcheon RA, Marques TR, Howes OD. Schizophrenia—an overview. JAMA Psychiat. 2020;77(2):201–10. https://doi.org/10.1001/jamapsychiatry.2019.3360.CrossRef

Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116(5):317–33. https://doi.org/10.1111/j.1600-0447.2007.01095.x.CrossRefPubMed

Van Os J, Kapur S. Schizophrenia Lancet. 2009;374:635–45. https://doi.org/10.1016/S0140-6736(09)60995-8.CrossRefPubMed

Chien IC, Chou YJ, Lin CH, Bih SH, Chou P, Chang HJ. Prevalence and incidence of schizophrenia among national health insurance enrollees in Taiwan, 1996–2001. Psychiatry Clin Neurosci. 2004;58:611–8. https://doi.org/10.1111/j.1440-1819.2004.01311.x.CrossRefPubMed

Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36:1535–40. https://doi.org/10.1017/S0033291706008191.CrossRefPubMed

Cho SJ, Kim J, Kang YJ, Lee SY, Seo HY, Park JE, et al. Annual prevalence and incidence of schizophrenia and similar psychotic disorders in the Republic of Korea: a national health insurance data-based study. Psychiatry investig. 2020;17(1):61. https://doi.org/10.30773/pi.2019.0041.CrossRefPubMedPubMedCentral

Messias EL, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am. 2007;30(3):323–38. https://doi.org/10.1016/j.psc.2007.04.007.CrossRefPubMedPubMedCentral

10.

Millier A, Schmidt U, Angermeyer MC, Chauhan D, Murthy V, Toumi M, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res. 2014;54:85–93. https://doi.org/10.1016/j.jpsychires.2014.03.021.CrossRefPubMed

11.

Merigó JM, Gil-Lafuente AM, Yager RR. An overview of fuzzy research with bibliometric indicators. Appl Soft Comput. 2015;27:420–33.CrossRef

12.

Astraud LP, Bridge JA, Jollant F. Thirty years of publications in suicidology: a bibliometric analysis. Arch Suicide Res. 2020. https://doi.org/10.1080/13811118.2020.1746944.

13.

Hao T, Chen X, Li G, Yan J. A bibliometric analysis of text mining in medical research. Soft Comput. 2018;22(23):7875–92.CrossRef

14.

Van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38. https://doi.org/10.1007/s11192-009-0146-3.CrossRefPubMed

15.

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76. https://doi.org/10.1093/schbul/13.2.261.CrossRefPubMed

16.

Kaufman J, Birmaher B, Brent D, Rao UMA, Flynn C, Moreci P, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980–988. https://doi.org/10.1097/00004583-199707000-00021.

17.

Lieberman JA, Stroup TS, McEvoy JP, Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. https://doi.org/10.1056/NEJMoa051688.CrossRefPubMed

18.

Ripke S, Neala, BM, Corvin A, Walters JTR, Farh KH, Holmans PA, et al. Schizophrenias Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511(7510):421–427. https://doi.org/10.1038/nature13595.

19.

Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–96.CrossRef

20.

Purcell S, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748–52. https://doi.org/10.1038/nature08185.

21.

Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153(3):321–30. https://doi.org/10.1176/ajp.153.3.321.CrossRefPubMed

22.

Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301–8. https://doi.org/10.1176/ajp.148.10.1301.CrossRefPubMed

23.

Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2000;26(1):119–36. https://doi.org/10.1093/oxfordjournals.schbul.a033430.

24.

Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426. https://doi.org/10.1037/0894-4105.12.3.426.CrossRefPubMedCentral

25.

Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 2001;98(12):6917–22. https://doi.org/10.1073/pnas.111134598.CrossRefPubMedPubMedCentral

26.

Andreasen NC, Olsen S. Negative v positive schizophrenia: Definition and validation. Arch Gen Psychiatry. 1982;39(7):789–94. https://doi.org/10.1001/archpsyc.1982.04290070025006.CrossRefPubMed

27.

Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry. 1986;43(2):114–24. https://doi.org/10.1001/archpsyc.1986.01800020020004.

28.

Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability Arch Gen Psychiatry. 1982;39(7):784–8. https://doi.org/10.1001/archpsyc.1982.04290070020005.CrossRefPubMed

29.

Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60(12):1187–92. https://doi.org/10.1001/archpsyc.60.12.1187.CrossRefPubMed

30.

Ripke S, Sanders AR, Kendler KS, Yang JC, Tanasa B, Li WWH, et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43(10):969. https://doi.org/10.1038/ng.940.CrossRef

31.

Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.CrossRef

32.

Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10(3):388–98. https://doi.org/10.1093/schbul/10.3.388.CrossRefPubMed

33.

Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdeletions associated with schizophrenia. Nature. 2008;455:232–6. https://doi.org/10.1038/nature07229.CrossRefPubMedPubMedCentral

34.

Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320(5875):539–43. https://doi.org/10.1126/science.1155174.CrossRefPubMed

35.

Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71(4):877–92. https://doi.org/10.1086/342734.CrossRefPubMedPubMedCentral

36.

Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 2009;373(9659):234–9. https://doi.org/10.1016/S0140-6736(09)60072-6.CrossRefPubMed

37.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. https://doi.org/10.1016/S0140-6736(08)61764-X.CrossRefPubMed

38.

Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000;157(1):16–25. https://doi.org/10.1176/ajp.157.1.16.CrossRefPubMed

39.

Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460(7256):744–7. https://doi.org/10.1038/nature08186.CrossRefPubMedPubMedCentral

40.

Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825–35. https://doi.org/10.1176/ajp.151.6.825.CrossRefPubMed

41.

Stone JL, et al. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008;455(7210):237–41. https://doi.org/10.1038/nature07239.

42.

Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry. 1990;47(2):181–8. https://doi.org/10.1001/archpsyc.1990.01810140081011.

43.

Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145(5):578–83. https://doi.org/10.1176/ajp.145.5.578.CrossRefPubMed

44.

Cohen JD, Servan-Schreiber D. Context, cortex, and dopamine: a connectionist approach to behavior and biology in schizophrenia. Psychol Rev. 1992;99(1):45–77. https://doi.org/10.1037/0033-295x.99.1.45.CrossRefPubMed

45.

Liddle PF. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry. 1987;151:145–51. https://doi.org/10.1192/bjp.151.2.145.

46.

Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000;57(1):65–73. https://doi.org/10.1001/archpsyc.57.1.65.CrossRefPubMed

47.

American Psychological Association. Diagnostic and statistical manual of mental disorders fourth edition: DSM-IV. Washington, DC; 1994.

48.

Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological reports. 1962;10(3):799–812. https://doi.org/10.2466/pr0.1962.10.3.799.CrossRef

49.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders (3rd ed., rev.). Washington, DC; 1987.

50.

Andreasen NC. Scale for the assessment of positive symptoms (SAPS). Iowa City: University of Iowa; 1984.

51.

Andreasen NC. Scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa; 1983.

52.

Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44(7):660–9. https://doi.org/10.1001/archpsyc.1987.01800190080012.CrossRefPubMed

53.

Oldfield RC. The assessment and analysis of handedness: The Edinburgh inventory. Neuropsychologia. 1971;9(1):97–113. https://doi.org/10.1016/0028-3932(71)90067-4.CrossRefPubMed

54.

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(20):22–33.PubMed

55.

Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. The J Clin Psychiatry. 2003;64(6):663–7. https://doi.org/10.4088/jcp.v64n0607.CrossRefPubMed

56.

Kiraz M. A Holistic Investigation of Global Outputs of Covid-19 Publications in Neurology and Neurosurgery. EJMI. 2020;4(4):506–12. https://doi.org/10.14744/ejmi.2020.36601.CrossRef

57.

Golpinar M, Demir E. Global research output of the cerebellum: Yesterday, today, and tomorrow. Journal of the Anatomical Society of India. 2020;69(3):155. https://doi.org/10.4103/JASI.JASI_114_20.CrossRef

58.

Sekar A, Bialas AR, De Rivera H, Davis A, Hammon TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177–83. https://doi.org/10.1038/nature16549.CrossRefPubMedPubMedCentral

59.

Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, & Gormley P. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506(7487):179-184. https://doi.org/10.1038/nature12929.

60.

Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, et al. polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506(7487):185–90. https://doi.org/10.1038/nature12975.CrossRefPubMedPubMedCentral

61.

Yang Y, Liu Y, Wang G, Hei G, Hei G, Wang X, et al. Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia. Psychiatry Res. 2019;273:528–36. https://doi.org/10.1016/j.psychres.2019.01.051.CrossRefPubMed

62.

Zhu S, Zhao L, Fan Y, Lv Q, Wu K, Lang X, et al. Interaction between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia. Psychoneuroendocrinology. 2020;114:104595. https://doi.org/10.1016/j.psyneuen.2020.104595.

63.

Kato TA, Monji A, Mizoguchi Y, Hashiok S, Horikawa H, Seki Y, et al. Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a ‘fire extinguisher’in the brain of schizophrenia? Mini Rev Med Chem. 2011;11(7):565–74. https://doi.org/10.2174/138955711795906941.CrossRefPubMed

64.

Juncal-Ruiz M, Riesco-Dávila L, de la Foz VOG, Ramírez-Bonilla M, Martínez-García O, Irure-Ventura J, et al. The effect of excess weight on circulating inflammatory cytokines in drug-naïve first-episode psychosis individuals. J Neuroinflammation. 2018;15(1):1–8. https://doi.org/10.1186/s12974-018-1096-6.CrossRef

65.

Kowalchuk C, Kanagasundaram P, McIntyre WB, Belsham DD, Hahn MK. Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons. Psychoneuroendocrinology. 2019;109109:104400. https://doi.org/10.1016/j.psyneuen.2019.104400.

66.

Fond G, Lançon C, Korchia T, Auquier P, Boyer L. The role of inflammation in the treatment of schizophrenia. Front Psychiatry. 2020;11:160. https://doi.org/10.3389/fpsyt.2020.00160.CrossRefPubMedPubMedCentral

67.

Nasib LG, Gangadin SS, Winter-van Rossum I, Boudewijns ZS, de Witte LD, Wilting I, et al. The effect of prednisolone on symptom severity in schizophrenia: A placebo-controlled, randomized controlled trial. Schizophr Res. 2021;230:79–86. https://doi.org/10.1016/j.schres.2021.01.024.CrossRefPubMed

Titel: Global Scientific Outputs of Schizophrenia Publications From 1975 to 2020: a Bibliometric Analysis
verfasst von: Seda Kiraz
Emre Demir
Publikationsdatum: 03.08.2021
Verlag: Springer US
Erschienen in: Psychiatric Quarterly / Ausgabe 4/2021
Print ISSN: 0033-2720
Elektronische ISSN: 1573-6709
DOI: https://doi.org/10.1007/s11126-021-09937-4

Neu im Fachgebiet Psychiatrie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

So wirken verschiedene Alkoholika auf den Blutdruck

23.05.2024 Störungen durch Alkohol Nachrichten

Je mehr Alkohol Menschen pro Woche trinken, desto mehr steigt ihr Blutdruck, legen Daten aus Dänemark nahe. Ob es dabei auch auf die Art des Alkohols ankommt, wurde ebenfalls untersucht.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Global Scientific Outputs of Schizophrenia Publications From 1975 to 2020: a Bibliometric Analysis

Abstract

Neu im Fachgebiet Psychiatrie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Demenzkranke durch Antipsychotika vielfach gefährdet

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

Update Psychiatrie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Communities of Practice in Acute and Forensic Psychiatry: Lessons Learned and Perceived Effects

Adjunctive Nonconvulsive Electrotherapy for Patients with Depression: a Systematic Review

Mental Imagery in Patients with Prolonged Grief Disorder: a Comparison with Matched Bereaved Healthy Controls

“I wouldn't even know what to do,” Adolescent and Parent Perspectives on Identifying, Understanding, and Seeking Help for Adolescent Depression

Beyond the Cuckoo’s Nest: Patient and Public Attitudes about Psychiatric Electroceutical Interventions

Virtual Reality Exposure Treatment in Phobias: a Systematic Review

Neu im Fachgebiet Psychiatrie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Demenzkranke durch Antipsychotika vielfach gefährdet

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

Update Psychiatrie